My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 641

    1.

    Effective treatment with oral sulfonylureas in patients with diabetes due to sulfonylurea receptor 1 (SUR1) mutations.

    Rafiq M, Flanagan SE, Patch AM, Shields BM, Ellard S, Hattersley AT; Neonatal Diabetes International Collaborative Group.

    Diabetes Care. 2008 Feb;31(2):204-9. Epub 2007 Nov 19.PMID: 18025408 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations.

    Pearson ER, Flechtner I, Njølstad PR, Malecki MT, Flanagan SE, Larkin B, Ashcroft FM, Klimes I, Codner E, Iotova V, Slingerland AS, Shield J, Robert JJ, Holst JJ, Clark PM, Ellard S, Søvik O, Polak M, Hattersley AT; Neonatal Diabetes International Collaborative Group.

    N Engl J Med. 2006 Aug 3;355(5):467-77.PMID: 16885550 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    Activating mutations in the ABCC8 gene in neonatal diabetes mellitus.

    Babenko AP, Polak M, Cavé H, Busiah K, Czernichow P, Scharfmann R, Bryan J, Aguilar-Bryan L, Vaxillaire M, Froguel P.

    N Engl J Med. 2006 Aug 3;355(5):456-66.PMID: 16885549 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    Diabetes and hypoglycaemia in young children and mutations in the Kir6.2 subunit of the potassium channel: therapeutic consequences.

    Flechtner I, de Lonlay P, Polak M.

    Diabetes Metab. 2006 Dec;32(6):569-80. Review.PMID: 17296510 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    Association studies of variants in promoter and coding regions of beta-cell ATP-sensitive K-channel genes SUR1 and Kir6.2 with Type 2 diabetes mellitus (UKPDS 53).

    Gloyn AL, Hashim Y, Ashcroft SJ, Ashfield R, Wiltshire S, Turner RC; UK Prospective Diabetes Study (UKPDS 53).

    Diabet Med. 2001 Mar;18(3):206-12. Erratum in: Diabet Med. 2003 Mar;20(3):252.. PMID: 11318841 [PubMed - indexed for MEDLINE]Related articles

    6.

    Diabetes in very young children and mutations in the insulin-secreting cell potassium channel genes: therapeutic consequences.

    Flechtner I, Vaxillaire M, Cavé H, Scharfmann R, Froguel P, Polak M.

    Endocr Dev. 2007;12:86-98.PMID: 17923772 [PubMed - indexed for MEDLINE]Related articles

    7.

    Sulfonylurea receptor 1 mutations that cause opposite insulin secretion defects with chemical chaperone exposure.

    Pratt EB, Yan FF, Gay JW, Stanley CA, Shyng SL.

    J Biol Chem. 2009 Mar 20;284(12):7951-9. Epub 2009 Jan 16.PMID: 19151370 [PubMed - indexed for MEDLINE]Related articles

    8.

    Carriers of an inactivating beta-cell ATP-sensitive K(+) channel mutation have normal glucose tolerance and insulin sensitivity and appropriate insulin secretion.

    Huopio H, Vauhkonen I, Komulainen J, Niskanen L, Otonkoski T, Laakso M.

    Diabetes Care. 2002 Jan;25(1):101-6.PMID: 11772909 [PubMed - indexed for MEDLINE]Related articlesFree article

    9.

    A rare mutation in ABCC8/SUR1 leading to altered ATP-sensitive K+ channel activity and beta-cell glucose sensing is associated with type 2 diabetes in adults.

    Tarasov AI, Nicolson TJ, Riveline JP, Taneja TK, Baldwin SA, Baldwin JM, Charpentier G, Gautier JF, Froguel P, Vaxillaire M, Rutter GA.

    Diabetes. 2008 Jun;57(6):1595-604. Epub 2008 Mar 17.PMID: 18346985 [PubMed - indexed for MEDLINE]Related articlesFree article

    10.

    A Kir6.2 mutation causing severe functional effects in vitro produces neonatal diabetes without the expected neurological complications.

    Tammaro P, Flanagan SE, Zadek B, Srinivasan S, Woodhead H, Hameed S, Klimes I, Hattersley AT, Ellard S, Ashcroft FM.

    Diabetologia. 2008 May;51(5):802-10. Epub 2008 Mar 12.PMID: 18335204 [PubMed - indexed for MEDLINE]Related articlesFree article

    11.

    Sulfonylurea receptor gene 16-3 polymorphism - association with sulfonylurea or insulin treatment in type 2 diabetic subjects.

    Zychma MJ, Gumprecht J, Strojek K, Grzeszczak W, Moczulski D, Trautsolt W, Karasek D.

    Med Sci Monit. 2002 Jul;8(7):CR512-5.PMID: 12118200 [PubMed - indexed for MEDLINE]Related articlesFree article

    12.

    New ABCC8 mutations in relapsing neonatal diabetes and clinical features.

    Vaxillaire M, Dechaume A, Busiah K, Cavé H, Pereira S, Scharfmann R, de Nanclares GP, Castano L, Froguel P, Polak M; SUR1-Neonatal Diabetes Study Group.

    Diabetes. 2007 Jun;56(6):1737-41. Epub 2007 Mar 27.PMID: 17389331 [PubMed - indexed for MEDLINE]Related articlesFree article

    13.

    Prevalence of permanent neonatal diabetes in Slovakia and successful replacement of insulin with sulfonylurea therapy in KCNJ11 and ABCC8 mutation carriers.

    Stanik J, Gasperikova D, Paskova M, Barak L, Javorkova J, Jancova E, Ciljakova M, Hlava P, Michalek J, Flanagan SE, Pearson E, Hattersley AT, Ellard S, Klimes I.

    J Clin Endocrinol Metab. 2007 Apr;92(4):1276-82. Epub 2007 Jan 9.PMID: 17213273 [PubMed - indexed for MEDLINE]Related articlesFree article

    14.

    [Polymorphism of the sulfonylurea receptor gene in type 2 diabetes mellitus]

    Owecki M, Horst-Sikorska W, Kaczmarek M, Słomski R, Sowiński J.

    Pol Arch Med Wewn. 2003 Feb;109(2):143-8. Polish. PMID: 12879777 [PubMed - indexed for MEDLINE]Related articles

    15.

    ABCC8 (SUR1) and KCNJ11 (KIR6.2) mutations in persistent hyperinsulinemic hypoglycemia of infancy and evaluation of different therapeutic measures.

    Darendeliler F, Fournet JC, Baş F, Junien C, Gross MS, Bundak R, Saka N, Günöz H.

    J Pediatr Endocrinol Metab. 2002 Jul-Aug;15(7):993-1000.PMID: 12199344 [PubMed - indexed for MEDLINE]Related articles

    16.

    Permanent neonatal diabetes due to mutations in KCNJ11 encoding Kir6.2: patient characteristics and initial response to sulfonylurea therapy.

    Sagen JV, Raeder H, Hathout E, Shehadeh N, Gudmundsson K, Baevre H, Abuelo D, Phornphutkul C, Molnes J, Bell GI, Gloyn AL, Hattersley AT, Molven A, Søvik O, Njølstad PR.

    Diabetes. 2004 Oct;53(10):2713-8.PMID: 15448106 [PubMed - indexed for MEDLINE]Related articlesFree article

    17.

    An ATP-binding mutation (G334D) in KCNJ11 is associated with a sulfonylurea-insensitive form of developmental delay, epilepsy, and neonatal diabetes.

    Masia R, Koster JC, Tumini S, Chiarelli F, Colombo C, Nichols CG, Barbetti F.

    Diabetes. 2007 Feb;56(2):328-36.PMID: 17259376 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.

    Impact of sulfonylurea receptor 1 genetic variability on non-insulin-dependent diabetes mellitus prevalence and treatment: a population study.

    Meirhaeghe A, Helbecque N, Cottel D, Arveiler D, Ruidavets JB, Haas B, Ferrières J, Tauber JP, Bingham A, Amouyel P.

    Am J Med Genet. 2001 Jun 1;101(1):4-8.PMID: 11343328 [PubMed - indexed for MEDLINE]Related articles

    19.

    The effects of mitiglinide (KAD-1229), a new anti-diabetic drug, on ATP-sensitive K+ channels and insulin secretion: comparison with the sulfonylureas and nateglinide.

    Sunaga Y, Gonoi T, Shibasaki T, Ichikawa K, Kusama H, Yano H, Seino S.

    Eur J Pharmacol. 2001 Nov 9;431(1):119-25.PMID: 11716850 [PubMed - indexed for MEDLINE]Related articles

    20.

    Analysis of two KCNJ11 neonatal diabetes mutations, V59G and V59A, and the analogous KCNJ8 I60G substitution: differences between the channel subtypes formed with SUR1.

    Winkler M, Lutz R, Russ U, Quast U, Bryan J.

    J Biol Chem. 2009 Mar 13;284(11):6752-62. Epub 2009 Jan 12.PMID: 19139106 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity